Introduction {#sec1-1}
============

Laryngeal cancer and hypopharyngeal cancer are two common malignancies of the head and neck. The incidence is increasing over time in much of the world. The diseases commonly occur in elderly patients. Most of laryngeal cancer and hypopharyngeal cancer are squamous cell carcinoma (SCC) followed by adenocarcinoma. The treatment modalities include surgery, radiotherapy and chemotherapy. Laryngectomy is the treatment of choice for locally intermediate to advanced laryngeal cancer and hypopharyngeal cancer.

Little published information is available concerning the clinicopathologic finding and treatment outcome of laryngeal cancer and hypopharyngeal cancer, particularly in Thailand. Most studies have been epidemiological in nature and only a few studies have been conducts with laryngectomy. Moreover, all of the published data are reported in the clinical aspect (Boonyaphiphat et al., 1994; Chitapanarux et al., 2014; Dechaphumkul et al., 2011; Jantharapattana, 2013; Ratanaanekchai and Reechaipichitkul, 2006). The clinicopathologic analysis of laryngeal cancer and hypopharyngeal cancer has not been well elucidated. The objectives of the present study were to evaluate the clinicopathologic findings and treatment outcome in laryngectomized patients with laryngeal cancer and hypopharyngeal cancer in Thailand.

At present, there are limited clinicopathologic data regarding the laryngeal cancer and hypopharyngeal cancer in Thailand (Boonyaphiphat et al., 1994;Chitapanarux et al., 2014; Dechaphumkul et al., 2011; Jantharapattana 2013; Ratanaanekchai and Reechaipichitkul, 2006). The objectives of the present study were to evaluate the clinicopathologic findings and treatment outcome in laryngectomized patients with laryngeal cancer and hypopharyngeal cancer in Thailand.

Materials and Methods {#sec1-2}
=====================

A total of 217 consecutive patients with laryngeal cancer and hypopharyngeal cancer, who were newly diagnosed and treated with laryngectomy at department of Otolaryngology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, between January 2000 and December 2010, were recruited in this study. However, complete clinical and pathologic records were available only in 212 patients. The authors reviewed the medical records and extracted information including age, gender, clinical manifestations, associated predisposing condition, histopathology and tumor grade according to World Health Organization (WHO) grade, tumor stage, maximum tumor size, anatomical involvement, type of surgery, postoperative sequelae, treatment and therapeutic outcome. Pathologic specimens of larynx and cervical lymph node were examined by pathologists (NL, DW, JL). The histopathologic diagnoses and anatomical involvement of laryngeal cancer and hypopharyngeal cancer were reviewed. Stages were defined according to the American Joint Committee on Cancer (AJCC) staging system. Further treatment depended on the malignant involvement of the cervical lymph node or the surgical margin not being free after attempted surgical resection. If they were involved then radiotherapy would be given. Chemotherapy was provided in addition to irradiation in patients who had advanced stage cancers with advance features including extracapsular tumor spread and/or positive surgical margin for tumor. Most of the patients were scheduled for post-treatment follow up every 1-3 months for 2 years and every 6 months afterward. All living patients who did not show up at the scheduled check up or loss to follow up were reminded by phone.

Patients were grouped based on primary lesion. Statistical analysis was performed using SPSS version 18.0. Categorical variables were compared using Chi-Square tests for association. A two-tailed Fisher's exact test was used to evaluate statistical significance between groups. The data of the patients between 2000 and 2006 were used to analyze for survival time and disease-free survival. Survival time was calculated from the date of beginning of laryngectomy until the date of death. Disease-free survival was calculated from the date of laryngectomy to the date of appearance of the new lesion. Survival profiles of the entire group and subgroup were examining using Kaplan-Meier method. The significance of differences in survival was evaluated using the log-rank test. Multivariate survival analysis was performed with the Cox proportional-hazards model. The present study was approved by the Ethical Clearance Committee on Human Rights Related to Researches Involving Human Subjects of Faculty of Medicine Ramathibodi Hospital, Mahidol University (ID 11-54-34).

Results {#sec1-3}
=======

Patient characteristics {#sec2-1}
-----------------------

Two hundred and twelve cases were found to meet the inclusion criteria. There were 155 cases of laryngeal cancer and 57 cases of hypopharyngeal cancer, affecting patients between 38 and 84 years with the mean age of 62.08 ± 9.67 years. The majority of patients were males (94.8%). One hundred and ninety patients (89.6%) were smokers. Demographic data of the patients presented in [Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Patients' Characteristics with Laryngeal Cancer and Hypopharyngeal Cancer

  Detail                                   Laryngeal cancer (n = 155)           Hypopharyngeal cancer (n = 57)                                               
  ---------------------------------------- ------------------------------------ -------------------------------------- ------------------------------------- ----------------------------------------
  Gender                                                                                                                                                     
   Male                                    147                                  94.8                                   54                                    94.7
   Female                                  8                                    5.2                                    3                                     5.3
  Clinical presentation                                                                                                                                      
   Hoarseness                              139                                  89.7                                   17                                    29.8
   Cervical lymphadenopathy                35                                   22.6                                   41                                    71.9
   Sorethroat                              14                                   9                                      33                                    57.9
   Odynophagia                             11                                   7.1                                    20                                    35.1
   Dyspnea                                 9                                    5.8                                    1                                     1.8
   Cough                                   7                                    4.5                                    2                                     3.5
   Weight loss                             6                                    3.9                                    4                                     7
   Dysphagia                               4                                    2.6                                    6                                     10.5
   Hemoptysis                              3                                    1.9                                    2                                     3.5
  Smoking                                  142                                  91.6                                   48                                    84.2
  Underlying diseases                                                                                                                                        
   Hypertension                            36                                   23.2                                   16                                    28.1
   Chronic obstructive pulmonary disease   25                                   16.1                                   11                                    19.3
   Pulmonary tuberculosis                  18                                   11.6                                   5                                     8.8
   Benign prostate hyperplasia             7                                    4.5                                    6                                     10.5
  Associated malignancy                                                                                                                                      
   Pulmonary carcinoma                     5                                    3.2                                    0                                     0
   Thyroid carcinoma                       0                                    0                                      1                                     1.8
  Histopathology                                                                                                                                             
   SCC, well-differentiated                123                                  79.4                                   33                                    57.9
   SCC, moderately-differentiated          21                                   13.5                                   13                                    22.8
   SCC, poorly-differentiated              5                                    3.2                                    9                                     15.7
   Basaloid SCC                            3                                    1.9                                    0                                     0
   Spindle cell carcinoma                  0                                    0                                      1                                     1.8
   Adenosquamous carcinoma                 1                                    0.6                                    1                                     1.8
   Atypical carcinoid tumor                1                                    0.6                                    0                                     0
   Polymorphous adenocarcinoma             1                                    0.6                                    0                                     0
  AJCC Stage                                                                                                                                                 
   Stage I                                 7                                    4.5                                    0                                     0
   Stage II                                35                                   22.6                                   6                                     10.5
   Stage III                               42                                   27.1                                   10                                    17.6
   Stage IV                                71                                   45.8                                   41                                    71.9
  T stage                                                                                                                                                    
   T1                                      11                                   7.1                                    3                                     5.3
   T2                                      38                                   24.5                                   24                                    42.1
   T3                                      47                                   30.3                                   18                                    31.6
   T4                                      59                                   38.1                                   12                                    21.1
  N stage                                                                                                                                                    
   N0                                      116                                  74.8                                   13                                    22.8
   N1                                      12                                   7.7                                    7                                     12.3
   N2                                      27                                   17.4                                   32                                    56.1
   N3                                      0                                    0                                      5                                     8.8
  Extracapsular tumor spread               15                                   9.7                                    21                                    36.8
  5-year survival rate                     55[\*](#t1f1){ref-type="table-fn"}   53.9[\*](#t1f1){ref-type="table-fn"}   9[\*\*](#t2f2){ref-type="table-fn"}   22.5[\*\*](#t2f2){ref-type="table-fn"}

Total 106 diagnosed cases before 2006, loss follow-up 4 cases

Total 41 diagnosed cases before 2006, loss follow-up 1 case

###### 

Patients' Characteristics with Laryngeal Cancer and Hypopharyngeal Cancer

  Detail                                            Laryngeal cancer (n = 155)                       Hypopharyngeal cancer (n = 57)
  ------------------------------------------------- ------------------------------------------------ --------------------------------------------------
  Mean age (years) ± SD                             61.5±9.4                                         63.8±10.2
  Preoperative hematocrit (%) ± SD                  39.3±5.3                                         39.9±5.5
  Maximum tumor size (cm.) ± SD                     2.6±1.4                                          3.4±1.3
  Nearest surgical margin (cm.) ± SD                0.7±0.5                                          0.5±0.3
  Total admission day (days) ± SD                   25.8±22.1                                        29.1±23.5
  Total postoperative admission day (days) ± SD     19.6±13.9                                        24.2±22.7
  Disease-free survival time with 95% CI (months)   61 (45.3-76.7)[\*](#t2f1){ref-type="table-fn"}   18 (6.9-29.1)[\*\*](#t2f2){ref-type="table-fn"}
   Stage I                                          99 (83.6-114.4)                                  \-
   Stage II                                         88 (68.6-107.4)                                  63 (30.8-95.2)
   Stage III                                        70 (52.2-87.8)                                   59 (39.6-78.4)
   Stage IV                                         18 (9.6-26.4)                                    11 (8.5-13.5)
  Median survival time with 95% CI (months)         67 (49.7-84.3)[\*](#t2f1){ref-type="table-fn"}   23 (13.7-32.3)[\*\*](#t2f2){ref-type="table-fn"}
   Stage I                                          118 (84.6-151.4)                                 \-
   Stage II                                         108 (78.1-137.9)                                 63 (30.8-95.2)
   Stage III                                        78 (60-96)                                       59 (39.6-78.4)
   Stage IV                                         29 (14.7-43.3)                                   16 (10.9-21.1)

Total 106 diagnosed cases before 2006, loss follow-up 4 cases

Total 41 diagnosed cases before 2006, loss follow-up 1 case

Clinical characteristics {#sec2-2}
------------------------

The clinical presentations were hoarseness (156 cases, 73.6%), cervical lymphadenopathy (76 cases, 35.8%), sorethroat (47 cases, 22.2%), odynophagia (31 cases, 14.6%), as shown in [Table 1](#T1){ref-type="table"}. The underlying diseases were hypertension (52 cases, 24.5%), chronic obstructive pulmonary disease (COPD) (36 cases, 17%), pulmonary tuberculosis (23 cases, 10.8%), benign prostatic hyperplasia (BPH) (13 cases, 6.1%), as shown in [Table 1](#T1){ref-type="table"}. Only one case was seropositive for human immunodeficiency viral (HIV) infection.

Anatomical involvements by tumor {#sec2-3}
--------------------------------

The extent of organ involvement included true vocal cord (147 cases, 69.3%), false vocal cord (105 cases, 49.5%), pyriform sinus (77 cases, 36.3%), and others, as shown in detail in [Table 3](#T3){ref-type="table"}. In laryngeal cancer and hypopharyngeal cancer, the greatest dimension of tumor size ranged between 0.2 to 8 and 1.3 to 8 cm, with the mean size of 2.6 ± 1.4 and 3.4 ± 1.3 cm, respectively. Lymph node metastasis was found in 40 and 45 patients (25.8% and 78.9%) of laryngeal cancer and hypopharyngeal cancer, respectively. Extracapsular tumor spread in metastatic laryngeal cancer and hypopharyngeal cancer was seen in 15 and 21 patients (9.7% and 36.8%), respectively. The distribution by AJCC surgical stage I, II, III and IV of laryngeal cancer was 4.5%, 22.6%, 27.1%, and 45.8%, respectively. The distribution by AJCC surgical stage II, III and IV of hypopharyngeal cancer was 10.5%, 17.6%, and 71.9%, respectively.

###### 

Anatomical Location of Lesions in The 212 Patients with Laryngeal Cancer and Hypopharyngeal Cancer

  Location                Laryngeal cancer[\*](#t3f1){ref-type="table-fn"} (n = 155)   Hypopharyngeal cancer[\*](#t3f1){ref-type="table-fn"} (n = 57)        
  ----------------------- ------------------------------------------------------------ ---------------------------------------------------------------- ---- ------
  True vocal cord                                                                                                                                            
   Right                  32                                                           20.6                                                             5    8.8
   Left                   33                                                           21.3                                                             4    7
   Bilateral              69                                                           44.5                                                             4    7
  False vocal cord                                                                                                                                           
   Right                  24                                                           15.5                                                             6    10.5
   Left                   26                                                           16.8                                                             6    10.5
   Bilateral              38                                                           24.5                                                             4    7
  Laryngeal ventricle                                                                                                                                        
   Right                  22                                                           14.2                                                             7    12.3
   Left                   25                                                           16.1                                                             4    7
   Bilateral              36                                                           23.2                                                             3    5.3
  Pyriform sinus                                                                                                                                             
   Right                  12                                                           7.7                                                              22   38.6
   Left                   9                                                            5.8                                                              23   40.4
   Bilateral              2                                                            1.3                                                              9    15.8
  Subglottis                                                                                                                                                 
   Right                  26                                                           16.8                                                             3    5.3
   Left                   15                                                           9.7                                                              1    1.8
   Bilateral              32                                                           20.6                                                             1    1.8
  Anterior commissure     102                                                          65.8                                                             1    1.8
  Posterior commissure    27                                                           17.4                                                             7    12.3
  Preepiglottic space     41                                                           26.5                                                             4    7
  Paraglottic space                                                                                                                                          
   Right                  21                                                           13.5                                                             14   24.6
   Left                   14                                                           9                                                                11   49.3
   Bilateral              20                                                           12.9                                                             1    1.8
   Epiglottis             21                                                           13.5                                                             10   17.6
  Aryepiglottic fold                                                                                                                                         
   Right                  18                                                           11.6                                                             17   29.8
   Left                   12                                                           7.7                                                              15   26.3
   Bilateral              7                                                            4.5                                                              1    1.8
   Vallecula              2                                                            1.3                                                              1    1.8
  Thyroid cartilage                                                                                                                                          
   Right                  16                                                           10.3                                                             3    5.3
   Left                   11                                                           7.1                                                              3    5.3
   Bilateral              10                                                           6.5                                                              0    0
  Cricoid cartilage                                                                                                                                          
   Right                  8                                                            5.2                                                              0    0
   Left                   3                                                            1.9                                                              1    1.8
   Bilateral              6                                                            3.9                                                              0    0
  Cricothyroid membrane                                                                                                                                      
   Right                  16                                                           10.3                                                             2    3.5
   Left                   11                                                           7.1                                                              3    5.3
   Bilateral              10                                                           6.5                                                              0    0
  Arytenoid cartilage                                                                                                                                        
   Right                  11                                                           7.1                                                              5    8.8
   Left                   11                                                           7.1                                                              4    7
   Bilateral              11                                                           7.1                                                              2    3.5
  Trachea                                                                                                                                                    
   Right                  2                                                            1.3                                                              0    0
   Left                   0                                                            0                                                                0    0
   Bilateral              2                                                            1.3                                                              0    0
  Thyroid gland                                                                                                                                              
   Right                  5                                                            3.2                                                              0    0
   Left                   0                                                            0                                                                1    1.8
   Bilateral              2                                                            1.3                                                              0    0

the patients may have one or more than one lesions

Histopathology {#sec2-4}
--------------

The histopathology of laryngeal cancer revealed well-differentiated SCC (79.4%), moderately-differentiated SCC (13.5%), poorly-differentiated SCC (3.2%), and basaloid SCC (1.9%). The histopathologic grade of hypopharyngeal cancer revealed well-differentiated SCC (57.9%), moderately-differentiated SCC (22.8%), and poorly-differentiated SCC (15.8%). The spindle cell carcinoma, adenosquamous carcinoma, atypical carcinoid tumor, and polymorphous adenocarcinoma had a small proportion. The details of histopathologic characteristics are displayed in [Table 1](#T1){ref-type="table"}.

Treatment and therapeutic outcome {#sec2-5}
---------------------------------

All patients underwent surgical laryngectomy. The surgical procedure varied from total laryngectomy (86.8%), supracricoid laryngectomy (8%), hemilaryngectomy (3.3%), frontolateral partial laryngectomy (0.9%) and extended epiglottectomy (0.9%). The average length of total hospitalization and postoperative stay was 26.7 and 20.9 days, respectively. The overall 5-year survival of laryngeal cancer and hypopharyngeal cancer was 53.9% and 22.5%, respectively. Radiotherapy and chemotherapy were given in 143 (67.5%) and 45 (21.2%) laryngectomized patients, respectively.

The postoperative sequelae related to laryngectomy were evaluated for all patients. The common postoperative sequelae was hypothyroidism (165 cases, 77.8%), followed by hypocalcemia (128 cases, 60.4%), and pharyngocutaneous fistula (12 cases, 5.7%).

The median follow-up time for the remaining 142 patients (2000-2006) was 48 months (range 1 to 142 months). Five patients had no complete follow-up data and therefore were excluded from the survival analysis. At the time of analysis, 64 patients (45.1%) were alive, 77 patients (54.2%) died of cancers and 1 patient (0.7%) died by accident. Of 147 patients, 51 (34.7%) developed recurrence. Distribution of recurrence and metastasis by site were as follows: lung in 30 patients (20.4%), tracheostoma in 16 patients (10.9%), cervical lymph node in 12 patients (9.4%), bone in 9 patients (6.1%), skin in 7 patients (4.8%), and liver in 3 patients (2%). The details of disease free survival and median survival time are shown in [Table 2](#T2){ref-type="table"}. The 5-year survival rate for node-negative cases was 61.8% versus 17% for node-positive cases (*p*\< 0.001), as shown in [Figure 1](#F1){ref-type="fig"}. The univariate analysis of 5-year survival was found to correlate with various clinicopathologic findings of 142 patients with laryngeal cancer and hypopharyngeal cancer, as shown in [Table 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}. The multivariate analysis of 5-year survival was correlated with various clinicopathologic findings of 142 patients with laryngeal cancer and hypopharyngeal cancer, as shown in [Table 6](#T6){ref-type="table"}.

![Disease-Specific 5-Year Survival Rates According to The Kaplan-Meier Method by Disease Stage (A, laryngeal cancer; B, hypopharyngeal cancer), and disease-specific 5-year survival rates according to the Kaplan-Meier method by extracapsular tumor spread; (C, laryngeal cancer; D, hypopharyngeal cancer).](APJCP-18-2035-g001){#F1}

###### 

Five-Year Survival Rate in The 142 Patients with Laryngeal Cancer and Hypopharyngeal Cancer Correlated with Clinicopathologic Findings

  Clinicopathologic findings                                      Laryngeal cancer (n = 102)   Hypopharyngeal cancer (n = 40)                      
  --------------------------------------------------------------- ---------------------------- -------------------------------- ------------------ -------
  Histopathology                                                                               0.036                                               0.863
   SCC, well-differentiated                                       49/82 (59.8%)                                                 6/25 (24%)         
   SCC, moderately-differentiated                                 5/13 (38.5%)                                                  1/7 (14.3%)        
   SCC, poorly-differentiated                                     0/5 (0%)                                                      2/7 (28.6%)        
   Adenosquamous carcinoma                                        0/1 (0%)                                                      0/1 (0%)           
   Atypical carcinoid tumor                                       1/1 (100%)                                                    \-                 
  AJCC Stage                                                                                   \<0.001                                             0.004
   Stage I                                                        7/7 (100%)                                                    \-                 
   Stage II                                                       18/21 (85.7%)                                                 3/5 (60%)          
   Stage III                                                      23/33 (69.7%)                                                 4/8 (50%)          
   Stage IV                                                       7/41 (17.1%)                                                  2/27 (7.4%)        
  T stage                                                                                      \<0.001                                             0.098
   T1                                                             7/8 (87.5%)                                                   0/2 (0%)           
   T2                                                             19/25 (76%)                                                   7/18 (38.9%)       
   T3                                                             23/34 (67.6%)                                                 2/10 (20%)         
   T4                                                             6/35 (17.1%)                                                  0/10 (0%)          
  N stage                                                                                      \<0.001                                             0.055
   N0                                                             51/80 (63.8%)                                                 5/10 (50%)         
   N1                                                             3/8 (37.5%)                                                   2/6 (33.3%)        
   N2                                                             1/14 (7.1%)                                                   2/22 (9.1%)        
   N3                                                             \-                                                            0/2 (0%)           
  Extracapsular tumor spread                                      1/9 (11.1%)                  0.011                            0/11 (0%)          0.043
  Smoking (%)                                                     51/94 (54.3%)                1                                8/36 (22.2%)       1
  Median survival time in smoking patients with 95% CI (months)   67.0 (48.0-86.0)                                              20.0 (11.8-28.2)   

###### 

Five-Year Survival Rate in Patients with Laryngeal Cancer and Hypopharyngeal Cancer Correlated with Anatomical Location of Cancer

  Location                Laryngeal cancer\* (n = 102)   Hypopharyngeal cancer[\*](#t5f1){ref-type="table-fn"} (n = 40)                  
  ----------------------- ------------------------------ ---------------------------------------------------------------- -------------- -------
  True vocal cord                                        0.083                                                                           0.654
   Positive               51/89 (57.3%)                                                                                   1/9 (11.1%)    
   Negative               4/13 (30.8%)                                                                                    8/31 (25.8%)   
  False vocal cord                                       0.003                                                                           1
   Positive               22/55 (40%)                                                                                     2/11 (18.2%)   
   Negative               33/47 (70.2%)                                                                                   7/29 (24.1%)   
  Laryngeal ventricle     0.073                                                                                           1              
   Positive               22/50 (44%)                                                                                     2/10 (20%)     
   Negative               33/52 (63.5%)                                                                                   7/30 (23.3%)   
  Subglottis                                             0.072                                                                           0.557
   Positive               19/44 (43.2%)                                                                                   0/4 (0%)       
   Negative               36/58 (62.1%)                                                                                   9/36 (25%)     
  Pyriform sinus                                         0.401                                                                           1
   Positive               6/14 (42.9%)                                                                                    9/39 (23.1%)   
   Negative               49/88 (55.7%)                                                                                   0/1 (0%)       
  Anterior commissure     0.674                                                                                           1              
   Positive               30/68 (44.1%)                                                                                   0/1 (0%)       
   Negative               17/34 (50%)                                                                                     9/39 (23.1%)   
  Posterior commissure    0.113                                                                                           1              
   Positive               6/17 (35.3%)                                                                                    0/3 (0%)       
   Negative               49/85 (57.7%)                                                                                   9/37 (24.3%)   
  Preepiglottic space     0.001                                                                                           1              
   Positive               5/22 (22.7%)                                                                                    1/4 (25%)      
   Negative               50/80 (62.5%)                                                                                   8/36 (22.2%)   
  Paraglottic space                                      0.003                                                                           0.707
   Positive               10/32 (31.3%)                                                                                   3/17 (17.7%)   
   Negative               45/70 (64.3%)                                                                                   6/23 (26.1%)   
  Epiglottis                                             0.041                                                                           0.175
   Positive               2/10 (20%)                                                                                      0/7 (0%)       
   Negative               53/92 (57.6%)                                                                                   9/33 (27.3%)   
  Aryepiglottic fold                                     0.327                                                                           0.134
   Positive               9/21 (42.9%)                                                                                    3/23 (13%)     
   Negative               46/81 (56.8%)                                                                                   6/17 (35.3%)   
  Vallecula                                              0.461                                                                           \-
   Positive               0/1 (0%)                                                                                        \-             
   Negative               55/101 (54.5%)                                                                                  9/40 (22.5%)   
  Thyroid cartilage                                      \<0.001                                                                         0.306
   Positive               3/21 (14.3%)                                                                                    0/6 (0%)       
   Negative               52/81 (64.2%)                                                                                   9/34 (26.5%)   
  Cricoid cartilage                                      0.295                                                                           1
   Positive               3/9 (33.3%)                                                                                     0/1 (0%)       
   Negative               52/93 (55.9%)                                                                                   9/39 (23.1%)   
  Cricothyroid membrane   0.008                                                                                           0.545          
   Positive               4/17 (23.5%)                                                                                    1/3 (33.3%)    
   Negative               51/85 (60%)                                                                                     8/37 (21.6%)   
  Arytenoid cartilage     0.056                                                                                           0.09           
   Positive               8/23 (34.8%)                                                                                    0/9 (0%)       
   Negative               47/79 (59.5%)                                                                                   9/31 (29%)     
  Trachea                                                0.21                                                                            \-
   Positive               0/2 (0%)                                                                                        \-             
   Negative               55/100 (55%)                                                                                    9/40 (22.5%)   
  Thyroid gland                                          0.094                                                                           1
   Positive               0/3 (0%)                                                                                        0/1 (0%)       
   Negative               55/99 (55.6%)                                                                                   9/39 (23.1%)   

the patients may have one or more than one lesions

###### 

Multivariate Analysis of Predictors of 5-Year Survival In Laryngeal Cancer and Hypopharyngeal Cancer

  Variables                    Laryngeal cancer\* (n = 102)   Hypopharyngeal cancer\* (n = 40)                                                           
  ---------------------------- ------------------------------ ---------------------------------- ------- ------- ------- ------- ------- ------- ------- -------
  Histopathology               0.12                           0.041                              1.277   1.01    1.615   0.195   0.407   1.175   0.802   1.721
  T stage                      0.126                          \<0.001                            1.692   1.323   2.164   0.229   0.007   1.856   1.185   2.908
  N stage                      0.225                          0.008                              1.823   1.173   2.834   0.229   0.047   1.576   1.006   2.469
  Extracapsular tumor spread   0.539                          0.778                              0.859   0.299   2.469   0.427   0.534   1.305   0.565   3.013

Discussion {#sec1-4}
==========

Laryngeal cancer and hypopharyngeal cancer are two common malignant cancers of the upper respiratory tract. The prevalence of laryngeal cancer and hypopharyngeal cancer is increasing. The authors have described our experience in managing 155 and 57 laryngectomized patients with laryngeal cancer and hypopharyngeal cancer, respectively. The mean age of these patients was 62.08 ± 9.67 years although the age range extended from 38 to 84 years; about 95% of the patients were more than 45 years. This age range is consistent with the previously reported age-group in which the age range of patients with laryngeal cancer was 29 to 90 years (Boonyaphiphat et al., 1994; Chitapanarux et al., 2014; Dechaphumkul et al., 2011; Jantharapattana 2013; Ratanaanekchai and Reechaipichitkul, 2006). The prevalence for laryngeal cancer and hypopharyngeal cancer seems to increase with age. Laryngeal cancer and hypopharyngeal cancer are nineteen times more common in men than in women (Boonyaphiphat et al., 1994; Chitapanarux et al., 2014; Dechaphumkul et al., 2011; Jantharapattana 2013; Ratanaanekchai and Reechaipichitkul, 2006). Smoking is the most important risk factor for laryngeal cancer and hypopharyngeal cancer. Ninety percent of our patients were smokers, in which there is more prevalence in laryngeal cancer than hypopharyngeal cancer. SCC is the most common malignant cell type in laryngectomized patients.

Laryngeal cancer is often detected at an early stage because complaints of hoarseness and change in voice occur relatively early in the nature of disease. Hypopharyngeal cancer provokes complaints in an advanced stage and the cervical lymphadenopathy is the most common presentation. The average maximum tumor size of hypopharyngeal cancer (3.4 ± 1.3 cm) was larger than that of laryngeal cancer (2.6 ± 1.4 cm). Therefore the overall prognosis in hypopharyngeal cancer was poorer than laryngeal cancer.

In accordance with many studies, the present data confirmed that the common postoperative sequelae was hypothyroidism (77.8%), followed by hypocalcemia (60.4%) and pharyngocutaneous fistula (5.7%) (Hall et al., 2003; Ratanaanekchai et al., 2004; Sparano et al., 2005). Moreover, in this study, there were five patients who developed hypercalcemia after laryngectomy with total thyroidectomy and parathyroidectomy. Hypothyroidism has been reported in up to one fourth of patients without adjunctive radiotherapy and in up to 70% with radiotherapy (Ho et al., 2008). Hypocalcemia caused by surgically induced hypoparathyroidism may occur with advertent removal of parathyroid glands during thyroidectomy. Hypercalcemia is an uncommon complication encountered, frequently associated with subsequent recurrence and systemic metastasis. The pathogeneses of hypercalcemic paraneoplastic syndrome include 1) bony osteolytic metastasis, which was found in only one case of this study; 2) the production of calcemic tumoral substance such as parathyroid hormone-related peptide, interleukin-1, transforming growth factor-alpha, tumor necrotic factor, and 1, 25-dihydroxyvitamin D, which could not be confirmed in the authors' study. It is important for the laryngologist to inform the patient that a relative frequency of postoperative sequelae could be encountered.

The prevalence of distant metastasis in laryngeal cancer was 7.2% and lung was the most common site (Yucel et al., 1999). In the present study, lung is also the most common metastasized site, followed by bone, skin, and liver. Stomal recurrence occurs in 1.7% to 14.7% of all patients who have undergone laryngectomies (Rubin et al., 1990; Esteban et al., 1993). In the authors' report, stomal invasion occurred in 10.9%. The precise pathogenesis of stomal recurrence remains unknown. The possible pathogeneses include: 1) unrecognized tumor at the surgical resected margin; 2) development of a second primary malignancy; 3) tumor implantation at the time of tracheostomy or primary surgery; and 4) recurrence secondary to metastases in the paratracheal or pretracheal lymph nodes (Barnes, 2009).

In previous studies, the prognostic value of other clinicopathologic variables (i.e., patient age, lesion size, histopathologic grade, margin status, surgical status of the cervical nodes, AJCC stage) has been demonstrated (Barnes et al., 2005; Barnes, 2009; Ramroth et al., 2011). The present study was able to show that advanced AJCC stage, advanced tumor status, advanced nodal status and tumor invasion of the false vocal cord, epiglottis, preepiglottic space, paraglottic space, thyroid cartilage, cricothyroid membrane were significantly associated with 5-year survival rate (*p*\< 0.001) in laryngeal cancer by univariate analysis, but the advanced nodal status did not affect the disease-free survival. These results are similar to previous reports (Barnes et al., 2005; Barnes, 2009; Ramroth et al., 2011) and additional demonstrate that the poor prognostic parameter of tumor-invasion of cricothyroid membrane, which is not describe in the recent WHO T-stage (Barnes et al., 2005).

Invasion of the laryngeal cartilages, T4, is an adverse prognostic indicator associated with an increased incidence of nodal metastasis. Cricothyroid membrane involvement is a sign of aggression of laryngeal cancer. This cricothyroid membrane is the soft tissue between cricoid and thyroid cartilages, which is easily tumor invasion more than the cartilaginous part of cricoid and thyroid cartilages. Normal laryngeal cartilage is resistant to tumor invasion because of its ability to release proteins that inhibit substances known to facilitate invasion such as collagenase, other proteinase and tumor angiogenetic factors (Kuettner et al., 1977). This cricothyroid involvement is a more common finding in T4 stage tumor. Moreover, there were 15 cases in laryngectomized patients with tumor invading cricothyroid membrane without laryngeal cartilaginous involvement in the present study. These patients had overall survival and disease free survival resembling T4 tumor status. The cricothyroid membrane invasion was significantly associated with decreased 5-year survival in laryngectomized patients with laryngeal cancer (*p* = 0.008). All laryngectomized specimens must be serially cut for searching tumor involvement of cricothyroid membrane.

The supraglottis including false vocal cord, preepiglottis, and epiglottis is richly supplied with lymphatic system whereas the glottis has little to no lymphatic drainage, which makes the cancer invading supraglottis more prone to have lymphatic metastasis. Moreover, the preepiglottic space is poorly vascularized (Fletcher and Hamberger, 1974). The anoxic concept of tumor invading preepiglottic space must be significant, possibly explaining the relative radioresistant, which also affects the survival. In the authors' series, laryngeal cancer involving false vocal cord, epiglottis and preepiglottic space was significantly associated with decreased 5-year survival rate. However there was no association in the case of hypopharyngeal cancer. Only advanced AJCC stage was significantly associated with 5-year survival in hypopharyngeal cancer (*p* = 0.004). This result is similar to previous data (Barnes et al., 2005; Barnes, 2009). Prognostic factors in laryngeal cancer are not significant in hypopharyngeal cancer because tumor invasion of the false vocal cord, epiglottis, preepiglottic space, paraglottic space, thyroid cartilage, cricothyroid membrane are uncommon site of invasion in hypopharyngeal cancer. Therefore, the result shows a statistically insignificant relationship between tumor invasion and 5-year survival. The other parameters including postcricoid and upper esophageal involvements are not included in our study, because there are only three case of postcricoid invasion and one case of esophageal invasion. Small sample sizes do not yield statistical significance.

The presence of extracapsular tumor spread should be determined by histopathologic examination of the lymphadenectomy specimen. The presence of extracapsular tumor spread in metastatic lymph nodes augments the risk of distant metastasis by nine times in laryngeal cancer and correlates with the 5-year survival (Oosterkamp et al., 2006). Extracapsular tumor spread may represent a biologic staging parameter that should be viewed as an aid in the selection of more-intensive or less-intensive radiotherapy. The occurrence of extracapsular tumor spread should be given in the pathologic report as TNEM (tumor, node, extracapsular tumor spread and metastasis) staging system. However, multivariate 5-year survival analysis of extracapsular tumor spread in both laryngeal cancer and hypopharyngeal cancer are not statistically significant (*p* = 0.778 and *p* = 0.534, respectively). The TNEM category might be helpful in better prognostic determination of laryngectomized patients. Prospective study of TNEM staging system of laryngeal cancer should be studied in more detail.

Since the present report was a retrospective study, some information was missing and incomplete. The limitation in the present study was varying technique of the surgical procedure including total laryngectomy, supracricoid laryngectomy, hemilaryngectomy, frontolateral partial laryngectomy, and extended epiglottectomy. However, most common surgical procedure was total laryngectomy (86.8%). Another limitation was the patients who were treated by various physicians over a long period of time. In addition, because the study period spans more than 10 years, the data may not represent current practice patterns, which tend to be minimally invasive and organ preservation surgery.

In conclusion, most patients with laryngeal cancer manifest with hoarseness. Cervical lymphadenopathy and odynophagia are commonly present in hypopharyngeal cancer. The advanced AJCC stage, advanced T stage, advanced N stage, extracapsular tumor spread, and tumor invasion of false vocal cord, epiglottis, preepiglottic space, paraglottic space, thyroid cartilage, and cricothyroid membrane significantly augment the decrease of 5-year survival in laryngeal cancer. Only advanced stage was significantly associated with 5-year survival rate in hypopharyngeal cancer. Accurate diagnosis of the pathological stage is essential for patient counseling and informed decision making. The authors believed that this report had provided clinicopathologic data for Thai laryngectomized patients with laryngeal cancer and hypopharyngeal cancer.
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